Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.4% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company specializing in CRISPR/Cas9 genome editing therapies. The market for NTLA today experienced a strong bearish movement.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.4% on Mar 19, 2026 14:26

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA

Farallon Capital Management LLC has acquired a new position of 607,200 shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA), valued at approximately $10.486 million, representing about 0.52% of the company's stock. Other institutional investors also increased their holdings, while company insiders sold shares totaling over $488,000 in the last ninety days. Intellia Therapeutics, a clinical-stage biotechnology company focused on CRISPR/Cas9 genome editing therapies, recently reported better-than-expected earnings, exceeding analyst revenue estimates.

https://www.marketbeat.com/instant-alerts/filing-farallon-capital-management-llc-purchases-shares-of-607200-intellia-therapeutics-inc-ntla-2026-03-16/

Trending Today

10x Genomics, Inc. ($TXG) Stock Forecast: Up 5.4% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 5.3% Today

Excelerate Energy ($EE) Stock Forecast: Down 5.8% Today

McKesson Corporation ($MCK) Stock Forecast: Down 5.4% Today

MicroVision Inc. ($MVIS) Stock Forecast: Up 11.0% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 5.2% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 8.5% Today

Fastly Inc. ($FSLY) Stock Forecast: Down 5.5% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 5.2% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 6.7% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.